The Freedom Portfolio – October 2019

October 11, 2019 paul.essen Comments 4 comments

It’s the one year anniversary of Paul vs the Market and the Freedom Portfolio! I just wish it could’ve coincided with a better performing quarter. The third quarter of 2019 was brutal, and saw the Freedom Portfolio essentially give back all of the gains from the 2nd quarter. The Freedom Portfolio was down 10.5% for the quarter, compared to the S&P being up around 1.7%. I’m still up versus the market year-to-date 22.9% to 20.5%, but am now back to losing to the market since inception (October of 2018) -4.1% to 3.9%.

Which brings me to something different that I want to do for this update: Instead of talking about the past quarter, I want to take a slightly longer term view and look at the performance since inception, which in this case is one year ago.

Below is table of the performance of the current positions in the Freedom Portfolio for the past year. For positions that I owned prior to October 2018, the starting price is the price on October 1st, 2018. For the positions that I acquired afterwards, the starting price is the price from the earliest date of purchase (since in some cases I bought shares multiple times). Here are the results:

Ticker	Start Price	Current Price	Percent Change
ABMD	191.68	177.89	-7.2%
AMZN	2021.99	1735.91	-14.1%
BABA	192.37	167.23	-13.1%
BZUN	49.3	42.7	-13.4%
CRSP	38.89	40.99	5.4%
DIS	117.28	130.32	11.1%
EDIT	23.43	22.74	-2.9%
GH	93.87	63.83	-32.0%
ILMN	369.15	304.22	-17.6%
IQ	27	16.13	-40%
ISRG	575.17	539.93	-6.1%
JD	26.03	28.21	8.4%
JMIA	18.91	7.93	-58.1%
KSHB	5.97	1.48	-75.2%
MDB	155.01	120.48	-22.3%
MELI	343.84	551.23	60.3%
NFLX	375.85	267.62	-28.8%
NPSNY	40.16	29.96	-25.4%
NVCR	52.94	74.78	41.3%
NVTA	17.6	19.27	9.5%
RDFN	18.56	16.84	-9.3%
SE	32.51	30.95	-4.8%
SHOP	166.44	311.66	87.3%
SQ	100.8	61.95	-38.5%
STNE	41.69	34.78	-16.6%
SWAV	53.12	29.93	-43.7%
TDOC	86.78	67.72	-22.0%
TSLA	305.77	240.87	-21.2%
TTD	214.75	187.55	-12.7%
TWLO	140.44	109.96	-21.7%

First, I want to point out an omission that I had trouble accounting for in the table above. Naspers (NPSNY) had an interesting (and complicated) quarter where they effectively spun off part of their business into another company called “Prosus” (PROSY) which is listing on the Amsterdam stock exchange (versus the Johannesburg stock exchange that Naspers is listed on). I won’t go into the details, but for each share of Naspers that I owned I now also own a share of Prosus as a result of the spin-off. However, when the split happened, the price of Naspers shares dropped a great deal (as one would expect). Therefore, the performance of Naspers above isn’t nearly as bad as it may seem.

Secondly, when looking at the performance of my positions over the past year, some of the numbers surprised me. There are typically three ways I look at the performance of my stocks: Daily (checking in on performance during my lunch break), Quarterly (during Freedom Portfolio check-ins), and Lifetime (since I bought the stock and not just from the beginning of the Freedom Portfolio).

So while I obviously know Netflix (NFLX) has had a rough past 6 months or so, it was still jarring to see the nearly 30% decline since the inception of the Freedom Portfolio. Why? Because I originally bought my shares of Netflix many years ago and so I’m used to thinking of it as a 400%+ out-performer and not an under-performer like it has been recently.

Netflix was probably the biggest discrepancy, but the story was similar across the board: Amazon (AMZN) was down 14% instead of being 300% up like I am used to seeing. Illumina (ILMN) down 17% instead of up 100%. There was even a big difference in the winners over the past year as well: Shopify (SHOP) was “only” up 87% instead of 600%+. It really drove home to me the important of a long term mindset that goes well beyond a single year. If I were to judge Netflix or Amazon on the performance over a single year, I probably would’ve sold it well before it had time to double, triple, and quadruple.

The first year I started closely following my investment returns, I just barely beat the S&P, but in the two years after I more than doubled the S&P 500’s return. I have consistently said, “I fully expect that there will be years where I lose to the market, sometimes badly.” While I didn’t lose to the market badly this first year, I did lose to it. Obviously I would’ve rather had a different outcome, but I am absolutely not deterred. I like the companies in the Freedom Portfolio right now even though many have seen pretty severe drops recently. I’m confidently that many of them will outperform over the next 5+ years and that some of them will outperform by a lot. I have a long term time horizon and that hasn’t changed at all with one disappointing year.

Now that that is out of the way, let’s get into some notable performers over the past year.

Notable Performers

Best Performers

Shopify (SHOP): It’s not a surprise to see Shopify as the top performer over the past year, as they’ve had quite an amazing run which saw the stock nearly triple in 2019 before giving back some of the gains in recent months. An 87% gain in a single year sounds impressive, but what’s even more impressive is that it’s up 600%+ since I bought it in 2017. The best might still be yet to come, too, with third party vendors looking for alternatives to Amazon and the building out of their fulfillment network. Looking forward to this being a major part of my portfolio for many years to come.

MercadoLibre (MELI): Also not surprising to see Mercado Libre up here, as it has also had an incredible run in 2019. The unrest in Argentina has hit the stock some recently, and the geo-political risk is as present as ever, but Mercado Libre still keeps finding a way to grow despite all the headwinds. I love being able to get an eCommerce play and digital payments play in the same company, and I also love getting exposure to the developing markets of South America. Can’t wait to see this company really soar once the situations in places like Argentina and Venezuela stabilize.

NovoCure (NVCR): This one might be a little bit of a surprise, since I don’t recall writing too much about Novocure in the past. The science fiction fan in me was initially attracted to the idea of fighting cancerous tumors with forcefields (or at least that’s how I prefer to think of them), but the investor in me loves how they continue to execute in getting their devices approved for more and more conditions.

Disney (DIS): A 10% gain might not seem that impressive, especially considering the ridiculous record breaking box office that Disney has had and all the hype around Disney+, but it was enough to make it a top 4 performer. Disney has weathered the market volatility better than most of my positions, and I’m excited to see what the next 12 months brings. Next year’s box office will almost certainly be considerably lower than this year’s, which could weigh on the stock, but we’ll also see the launch of Disney+ in November and start getting some subscriber numbers. I expect Disney is going to crush it with their numbers and beat even the optimistic expectations. We’ll find out in a few months.

Worst Performers

KushCo Holdings (KSHB): Thank goodness KushCo started off as one of my smaller holdings. The stock has gotten crushed recently, losing half its value in just a few months. The main culprit seems to be the sudden backlash to vaping, but I also have some slight concerns about solvency based on some of the recent actions the company has taken. I’m still holding on for now, as the long term thesis could still be intact assuming we don’t see a full on ban on vaping and the movement towards marijuana legalization continues, but the risks have definitely increased with this one.

Jumia Technologies (JMIA): Jumia is the poster child for not getting caught up in a recent IPO and waiting a few months before jumping in. Luckily, I didn’t buy anywhere near the high of around $40 a share because I realized it was an absurd valuation for such an unproven company. Still, I’m down on all of my purchases so I should’ve been even more cautious. Also, maybe I should give more thought to when lock-up periods end. Still, I am a sucker for eCommerce and developing markets, so I’m still holding onto my shares and looking for better days (and years) ahead.

ShockWave Medical (SWAV): Another cautionary tale of buying a recent IPO too soon. This time I unfortunately bought much closer to the high. I suspect I saw a lot of similarities to NovoCure (one of my top performers above) and got too carried away. Both are medical device companies with really innovative solutions to widespread problems. I still like the future prospects of the company and plan on holding, I just wish I had been more patient so I could’ve bought shares cheaper.

iQiyi (IQ): I suppose iQiyi could also be considered a relatively recent IPO (early 2018) that in retrospect I should’ve waited longer to buy. It’s hard to disentangle how much of iQiyi’s performance lately is due to the performance of the company or larger concerns over China. I haven’t seen anything in the company’s performance which overly concerns me yet, although the competition remains a concern.

Square (SQ): This one is a head scratcher to me. I’m having a hard time understanding why Square has floundered so much recently, especially in comparison to Shopify, which has soared. Square seems to be in a great position, with their Cash app, to appeal to the un-banked and under-banked and be a major player in the digital payments space. Hard to see how this is anything more than just a temporary setback.

Changes in the Portfolio

Sells

Uxin (UXIN): The short story is that I found other investments that I preferred having my money in. I still think Uxin is an interesting story and will keep tabs on it and may return at some point in the future, but there were more interesting companies that I wanted to be invested in. As a result, I sold my entire position.

Markel (MKL): Similar to Uxin, I saw better opportunities elsewhere. I do think Markel will be a market beater long term, but there are other companies that I think will beat the market by an even larger margin, and I wanted to invest in those instead. I sold my entire position.

Netflix (NFLX): This one hurt. Netflix has been one of my longest term holdings and is a company that I have a long and storied history with. At points I even swore that I would never sell any shares ever again. I only sold a part of my position, and it still remains a sizeable holding for me. I still believe it will be a long term winner, and I also think the recently correction is overdone, but I do worry that lower cost competition from Disney and Apple will hurt Netflix’s ability to raise prices, which will hamper their growth prospects some.

Intuitive Surgical (ISRG): I sold about a third of my position largely because I wanted some cash to purchase something else and this was one of my lower conviction ideas at the time.

Illumina (ILMN): Similar to Intuitive Surgical above, I also only sold about a third of my Illumina position. I had a more specific reason for Illumina, though. Their most recent earnings report had some warning flags in terms of slowing growth that had me worried.

Buys

Alibaba (BABA): Nothing fancy. Alibaba has been pretty flat for the past year despite posting some pretty nice earnings reports during that time and continuing to grow at an impressive rate. Once sentiment on China turns away from being so negative, this feels like a stock that could really rebound nicely.

Jumia Technologies (JMIA): It wasn’t surprising to see Jumia fall so much after the crazy run-up in the immediate aftermath of their IPO. Even though my initial position is down almost 50%, I’m still intrigued by the potential of the so-called “Amazon of Africa”, and so decided to add a little to my position. It remains one of my smallest positions, though.

The Trade Desk (TTD): The Trade Desk continues to grow like gangbusters, even if the stock has been relatively flat recently. I still like the long term story, though, so I added to my position.

Square (SQ): Square had a rough quarter which saw the stock price plummet after what looked like a pretty good earnings report. I’m not sure I understand what the market is thinking here, and still like a lot of the things they’re working on like the rumored stock trading functionality to the Cash app and acquiring a banking license. I added a bit to my position.

Shockwave Medical (SWAV): Similar to Jumia, Shockwave has also had a big pullback after a huge run-up post-IPO. I see nothing which changes my original investment thesis, and I suspect this is just a little post-IPO enthusiasm wearing off, so I lowered my cost basis some.

Abiomed (ABMD), MongoDB (MDB), Twilio (TWLO), Guardant Health (GH), Sea Limited (SE): All new positions, and all small ones at that. They range from more medical companies (ABMD and GH) to Software as a Service (SaaS) companies (MDB and TWLO) to another eCommerce play (SE). I might write more about some of these later depending on how things go, but for now they’re too small to spend too much time discussing.

Other

Naspers (NPSNY) and Prosus (PROSY): As mentioned previously, I acquired shares of Prosus as a result of a spin-off by Naspers. I plan on holding both for now, although at some point I might end up simplifying things by selling one or the other.